QuantHealth has raised $45 million to expand an AI platform that simulates clinical trials before a single real patient is enrolled — a bid to cut the enormous waste in drug development.
The Series B round, announced this week, was led by Qumra Capital, with Sanofi Ventures, Pitango HealthTech and others participating. It brings QuantHealth’s total funding to $70 million since it was founded in 2020.
What it does
QuantHealth’s system builds virtual simulations of trials, predicting how patients would respond to a treatment and flagging design changes — different endpoints, patient populations or protocols — that could raise the odds of success. It pairs AI with large biomedical knowledge graphs and uses transfer learning to extend predictions to rare diseases and small patient groups where data are scarce. The company says it has simulated more than 600 trials across 30 disease areas, with up to 90% accuracy in predicting patient outcomes — figures it reports itself.
Why it matters
“The clinical stage of drug development has remained largely untouched by AI innovation,” said CEO Orr Inbar. Roughly 90% of clinical trials fail, an enormously costly problem; catching flawed designs early could spare patients from ineffective treatments and speed useful drugs along. QuantHealth plans to use the money to improve its models, cover more diseases, and extend into drug positioning and commercialization. As with any predictive platform, the real test is whether its forecasts hold up against actual trial outcomes.